Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis

Note: Funding Information: Patients included in this manuscript participated in the BioDay registry sponsored by Sanofi Genzyme.Conflicts of interest: D. Bakker, J. Thijs, J. van der Schaft, and C. van Luijk are speakers for Sanofi Genzyme. J. de Boer received research funding from Abbvie; this is outside the submitted work. D. Balak is a speaker and/or advisor for AbbVie, Leo Pharma, Regeneron, and Sanofi-Genzyme. M. de Graaf is a principal investigator and advisory board member for Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.; and is an advisory board member for Eli Lilly. M. de Bruin-Weller is a principal investigator, advisory board member, and consultant for AbbVie, Regeneron Pharmaceuticals Sanofi-Genzyme, and Leo Pharma; is an advisory board member and consultant for Eli Lilly, UCB, and Galderma; and is a principal investigator and advisory board member for Pfizer. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: Conflicts of interest: D. Bakker, J. Thijs, J. van der Schaft, and C. van Luijk are speakers for Sanofi Genzyme. J. de Boer received research funding from Abbvie ; this is outside the submitted work. D. Balak is a speaker and/or advisor for AbbVie, Leo Pharma, Regeneron, and Sanofi-Genzyme. M. de Graaf is a principal investigator and advisory board member for Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.; and is an advisory board member for Eli Lilly. M. de Bruin-Weller is a principal investigator, advisory board member, and consultant for AbbVie, Regeneron Pharmaceuticals Sanofi-Genzyme, and Leo Pharma; is an advisory board member and consultant for Eli Lilly, UCB, and Galderma; and is a principal investigator and advisory board member for Pfizer. The rest of the authors declare that they have no relevant conflicts of interest.